| Literature DB >> 34071402 |
Swinburne A J Augustine1, Tarsha N Eason2, Tim Wade3, Shannon M Griffin1, Elizabeth Sams3, Kaneatra Simmons4, Malini Ramudit5, Kevin Oshima6, Alfred Dufour6.
Abstract
Detecting environmental exposures and mitigating their impacts are growing global public health challenges. Antibody tests show great promise and have emerged as fundamental tools for large-scale exposure studies. Here, we apply, demonstrate and validate the utility of a salivary antibody multiplex immunoassay in measuring antibody prevalence and immunoconversions to six pathogens commonly found in the environment. The study aimed to assess waterborne infections in consenting beachgoers recreating at an Iowa riverine beach by measuring immunoglobulin G (IgG) antibodies against select pathogens in serially collected saliva samples. Results showed that nearly 80% of beachgoers had prior exposures to at least one of the targeted pathogens at the beginning of the study. Most of these exposures were to norovirus GI.1 (59.41%), norovirus GII.4 (58.79%) and Toxoplasma gondii (22.80%) and over half (56.28%) of beachgoers had evidence of previous exposure to multiple pathogens. Of individuals who returned samples for each collection period, 6.11% immunoconverted to one or more pathogens, largely to noroviruses (GI.1: 3.82% and GII.4: 2.29%) and T. gondii (1.53%). Outcomes of this effort illustrate that the multiplex immunoassay presented here serves as an effective tool for evaluating health risks by providing valuable information on the occurrence of known and emerging pathogens in population surveillance studies.Entities:
Keywords: Buffalo Shores Beach; Iowa; Luminex; coinfection; environmental pathogens; immunoassay; immunoconversion; immunoprevalence; incident infection; multiplex; population surveillance; public health; recreational beach; saliva; waterborne
Year: 2021 PMID: 34071402 PMCID: PMC8199218 DOI: 10.3390/ijerph18115797
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Multiplex immunoassay reagents, commercial sources, and concentrations.
| Organism | Antigen (Ag) | Source | Amt. of Ag Coupled (µg) |
|---|---|---|---|
| Hepatitis A virus | Cell culture concentrate | Meridian | 100 |
| Norovirus GI.1 | P-particle | Xi Jiang * | 5 |
| Norovirus GII.4 | P-particle | Xi Jiang * | 5 |
|
| Heat-killed whole bacterial cells | KPL | 50 |
|
| Bacterial cell lysate | Meridian | 25 |
|
| Recombinant p30 (SAG1) | Meridian | 25 |
* Jiang Lab, Cincinnati Children’s Hospital, Cincinnati, OH, USA. Ag refers to antigen type. Source references where antigens were purchased. Amt. of Ag Coupled denotes the concentration of antigens coupled to each bead set. KPL refers to Kirkegaard Perry Labs; SAG-1 (Surface Antigen-1).
Figure 1Maps of (A) the United States displaying the study area on the eastern border of Iowa. (B) The study area (lower left in dark blue) is along the Mississippi River downstream from Davenport, Iowa, and multiple wastewater treatment plants (WWTP). (C) A snapshot of the Buffalo Shores Beach recreational area.
Communities contributing sewage (in gallons per day: GPD) to the Mississippi River upstream of Buffalo Shores Beach.
| Community | Population | Plant Capacity | Treatment | Chlorination |
|---|---|---|---|---|
| Moline, IL, N 1 | 43,483 * | 1,375,000 GPD | Secondary | Yes |
| Rock Island, IL | 39,018 | 16,000,000 GPD | Tertiary | Yes |
| Milan, IL | 5099 | 1,000,000 GPD | Secondary | Yes |
| Moline, IL, S 1 | 43,483 * | 1,800,000 GPD | Secondary | Yes |
| Colona, IL | 5099 | 1,000,000 GPD | Secondary | Yes |
| East Moline, IL | 21,302 | 11,100,000 GPD | Secondary | Yes |
| Davenport, IA | 127,142 | 20,000,000 GPD | Secondary | No |
| Buffalo, IA | 1260 | 130,000 GPD | Secondary | Yes |
Source: Information obtained from the various community websites at the time study began. * only includes half of the Moline, IL population. 1 N indicates the north sewage treatment plant. S indicates the south sewage treatment plant.
Figure 2Immunoprevalence for targeted pathogens. (A) Median Fluorescence Intensity units (MFI) scatterplot showing all S1 samples with the cutoff (red line: 739.02 MFI) distinguishing positive (above) and negative (below) samples. (B) Immunoprevalence heatmap displaying the positive samples denoted by black lines.
Immunoprevalence summary provides an overview of the baseline (S1) exposure to the pathogens under study. Top: individuals with exposure to none, any, single or multiple pathogens. Middle: individuals with exposure to N (0 to 6) pathogens, where N ≥ 2 denotes the individuals with exposures to multiple pathogens. Bottom: individuals with exposure to specific pathogens.
| Immunoprevalence |
| % | |
|---|---|---|---|
| None | 102 (21.34) | 102 | 21.34% |
| Any (N ≥ 1) | 376 (78.66) | 376 | 78.66% |
| Single (N = 1) | 107 (22.38) | 107 | 22.38% |
| Multiple (N ≥ 2) | 269 (56.28) | 269 | 56.28% |
| To N pathogens | |||
| N |
| % | |
| 0 | 102 (21.34) | 102 | 21.34% |
| 1 | 107 (22.38) | 107 | 22.38% |
| 2 | 149 (31.17) | 149 | 31.17% |
| 3 | 82 (17.15) | 82 | 17.15% |
| 4 | 29 (6.07) | 29 | 6.07% |
| 5 | 7 (1.46) | 7 | 1.46% |
| 6 | 2 (0.42) | 2 | 0.42% |
| To specific pathogens | |||
| Pathogen |
| % | |
|
| 9 (1.88) | 9 | 1.88% |
|
| 109 (22.80) | 109 | 22.80% |
|
| 71 (14.85) | 71 | 14.85% |
| Hep. A | 60 (12.55) | 60 | 12.55% |
| NoV GII.4 | 281 (58.79) | 281 | 58.79% |
| NoV GI.1 | 284 (59.41) | 284 | 59.41% |
Note: “n” denotes number of individuals and “N” denotes number of pathogens.
Co-immunoprevalence: Number and percentage of individuals with samples that are positive to two (N = 2) pathogens at S1.
|
|
|
| HAV | NoV GII.4 | NoV GI.1 | |
|---|---|---|---|---|---|---|
|
| 4 (0.84%) | 5 (1.05%) | 5 (1.05%) | 8 (1.67%) | 8 (1.67%) | |
|
| 29 (6.07%) | 23 (4.81%) | 65 (13.60%) | 79 (16.53%) | ||
|
| 11 (2.30%) | 50 (10.46%) | 61 (12.76%) | |||
| HAV | 52 (10.88%) | 53 (11.09%) | ||||
| NoV GII.4 | 216 (45.19%) | |||||
| NoV GI.1 |
Figure 3Immunopositivity summary: exposure status of the individuals who provided a saliva sample for each collection period (S1–S3). Upper panel: black lines represent the samples positive (MFI ≥ cutoff) for the targeted pathogens. Lower panel: % immunopositivity for the targeted pathogens.
Immunoconversions (IC): number (n) and percentage (%) of individuals who immunoconverted to the pathogens based on the established criteria: S2 ≥ 4 × S1; S2 ≥ cutoff; S3 ≥ 3 × S1.
| Immunoconversions |
| % | |
|---|---|---|---|
| None | 123 (93.89) | 123 | 93.89% |
| Any (N ≥ 1) | 8 (6.11) | 8 | 6.11% |
| Single (N= 1) | 4 (50) | 4 | 50% |
| Multiple (N ≥ 2) | 4 (50) | 4 | 50% |
| To N pathogens | |||
| N |
| % | |
| 0 | 123 (93.89) | 123 | 93.9% |
| 1 | 4 (3.05) | 4 | 3.05% |
| 2 | 4 (3.05) | 4 | 3.05% |
| 3 | 0 (0.00) | 0 | 0% |
| 4 | 0 (0.00) | 0 | 0% |
| 5 | 0 (0.00) | 0 | 0% |
| 6 | 0 (0.00) | 0 | 0% |
| To specific pathogens | |||
| Pathogen |
| % | |
|
| 0 (0.00) | 0 | 0% |
|
| 2 (1.53) | 2 | 1.53% |
|
| 1 (0.76) | 1 | 0.76% |
| HAV | 1 (0.76) | 1 | 0.76% |
| NoV GII.4 | 3 (2.29) | 3 | 2.29% |
| NoV GI.1 | 5 (3.82) | 3 | 3.82% |
Figure 4Immunoconversion summary denoting the number of immunoconversions and co-immunoconversions to the pathogens under study. Note Tg: T. gondii; GI.1: norovirus GI.1; GII.4: norovirus GII.4; HAV: hepatitis A virus and Hp: H. pylori.
Figure 5MFI curves for the pathogens under study. Plots showing IgG in MFI from S1 to S3 for immunoconversions. Red dashed line = cutoff (739.02 MFI).